In­ves­tiga­tive re­port calls for re­newed scruti­ny on Aca­dia drug; Im­bru­vi­ca fails in front­line DL­B­CL PhI­II

→ The spot­light on Aca­dia Phar­ma­ceu­ti­cals’ $ACAD Parkin­son’s drug has turned more in­tense as in­ves­tiga­tive jour­nal­ist Rod­dy Boyd (you might re­mem­ber his re­port­ing on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER